ChinaBio Today -- Recently, at the ChinaBio® Partnering Forum held in Shanghai, an event devoted to encouraging biopharma transactions of the partnering variety, the Keynote Panel discussed significant issues surrounding China partnering deals (see story). The panel was moderated by Gerald Chan, DSc, of Morningside Group, a long-standing member of the China venture capital and private equity worlds. Dr. Chan took advantage of his dual insider/outsider roles to ask difficult questions, particularly asking the question of whether China’s science is as good as people say. Under his direction, the panel discussed innovation and the state of China's bioscience, the problems that big pharma faces and causes when it comes to China, and the business model that best encourages partnership.
